MRK

Dividend Increases/Decreases for the Week Ending November 27

by

Below we provide a list of firms that raised/lowered their dividends during the week ending November 27. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week Becton, Dickinson (BDX): now $0.66 per share quarterly dividend, was $0.60. Capital City Bank (CCBG): now $0.04 per share quarterly dividend, was $0.03. Citizens Community Bank (CZYB): now $0.07 per share annual dividend, was $0.05. Ferrellgas Partners (FGP): now $0.5125 per share quarterly dividend, was $0.51. Hormel Foods (HRL): now $0.29 per share quarterly dividend, was $0.25. Laclede Group, Inc. (LG): now $0.49 per share quarterly … Read more

Around the Horn in Biotech/Pharma: 3Q Earnings Review

by

The biotech (IBB) and pharma (XLV) industries have been two of the strongest-performing segments of the market since the March 2009 panic bottom during the Financial Crisis, but the broader healthcare arena has been under siege as of late. New discoveries underscored by the development of a cure for hepatitis C with Gilead’s (GILD) Solvadi/Harvoni and a huge step forward in cystic fibrosis treatment with Vertex’s (VRTX) Orkambi have helped fuel the exuberance, but established pharma entities have also caught a bid as they successfully worked through the “patent cliff,” capturing the wave of dividend growth investors and acquiring budding new pipelines from smaller rivals along the way. The past few months haven’t been kind to biotech investors, however. What … Read more

If It Happened to AbbVie, Could It Also Happen to Gilead?

by

The Valeant (VRX) and Citron saga is not all the drama happening in biotech these days. On October 22, federal health officials warned doctors and patients that two of AbbVie’s (ABBV) hepatitis C treatments can cause life-threatening liver injury in advanced stage patients. The Food and Drug Administration announced October 22 that it will require AbbVie to add new warnings to its Viekira Pak (1) and Technivie (2) drugs after deaths and liver transplants have been reported in patients who already had liver damage caused by the disease. During the second quarter, global sales of Viekira were $385 million, on pace for blockbuster status. Viekira is one of AbbVie’s top drugs, trailing only Humira in sales during the six months … Read more

Video: Are Economic Moats Priced Into Stock Prices? — You Bet They Are

by

President of Equity Research Brian Nelson debunks the myth that the economic moat is not included in stock prices. Length: ~8 minutes. Tickerized for firms in the Morningstar Wide Moat ETF (MOAT), as of October 14, 2015. Brian Nelson, CFA: This is Brian Nelson from Valuentum Securities. I wanted to talk about an important concept and answer an important question. Is Warren Buffet’s economic moat priced into stock prices? Before I answer that question, I think we need to define a couple things. Return on invested capital is a measure of a business’ performance. It’s calculated as earnings before interest divided by net new investment, which is a measure of return on new invested capital. So what is the return the … Read more

Big Pharma Earnings Continued…

by

Amgen (AMGN) Amgen’s second-quarter results, released July 30, were a sight to see. Total revenue advanced 4% versus the second quarter of last year thanks to strength in Enbrel (etanercept), Prolia (denosumab), Sensipar (cinacalcet), Kyprolis (carfilzomib) and XGEVA (denosumab). Adjusted operating income and adjusted earnings per share leapt 10% and 8% in the quarter thanks in part to the strong top-line performance but also solid adjusted operating margin improvement (~+2 percentage points). Free cash flow generation was also fantastic, with the firm hauling in $2.7 billion in the measure compared to $2.1 billion in the second quarter of 2014. Keys to the Quarter: Investors should keep an eye on its blockbuster Neulasta/NEUPOGEN performance, which faced sales pressure in the quarter, … Read more

Is Apple Worth More Than $200 Per Share?

by

Possibly. But we do think Apple’s stock is cheap. $727 billion. $727,000,000,000. That’s Apple’s (AAPL) market capitalization as of the close of business February 11. It’s hard to put such a huge number into perspective, but it amounts to roughly the market caps of the next two largest companies on the US market, Exxon Mobil (XOM) and Microsoft (MSFT), combined. From our perspective, Apple is finally getting credit for its sprawling and near-impenetrable ecosystem and dominance in converging technologies from the iPhone to the iPad to wearable devices. In his latest open letter that’s making headlines, Carl Icahn upped his fair value estimate of Apple to $216 from $203 due in part to higher-than-previously-forecast earnings estimates for the current fiscal … Read more

HCV Competition Not New “News” for Gilead

by

Let’s set one thing straight. On a fundamental basis, biotech firm Gilead Sciences (GILD) is performing quite well, contrary to what its recent stock price move might suggest. Prescriptions for the firm’s Harvoni and Sovaldi hepatitis-C drugs continue to track slightly ahead of projections, and we would expect a slightly stronger-than-forecast fourth-quarter report as a result. In coming periods, we look forward to positive management commentary that speaks to the strength and sustainability of the firm’s hepatitis-C franchise (about half of Gilead’s sales). Any commentary, in light of the recent uncertainty and growing competition in the hepatitis C market, will be reassuring for investors that have been anxiously pursuing tax-loss selling and profit-taking in Gilead’s shares the past few weeks. … Read more

Dividend Increases for the Week Ending November 28

by

Below we provide a list of firms that raised their dividends during the week ending November 28. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week Becton, Dickinson (BDX): now $0.60 per share quarterly dividend, was $0.545. Capital City Bank (CCBG): now $0.03 per share quarterly dividend, was $0.02. Glacier Bancorp (GBCI): now $0.18 per share quarterly dividend, was $0.17. Hormel Foods (HRL): now $0.25 per share quarterly dividend, was $0.20. McCormick & Company (MKC): now $0.40 per share quarterly dividend, was $0.37. Merck (MRK): now $0.45 per share quarterly dividend, was … Read more

Big Pharma Round Up

by

Though much has been made about the patent cliff—shorthand for the expiration of the patents of a large number of drugs over a short period of time—we continue to believe that pipelines across much of the pharmaceutical space are flush with new drugs and therapies. Readers may have an individual favorite or two (or three) within the space (and there’s nothing wrong with that), but we think one of the best ways for investors to play the strong pipelines across the healthcare sector—and ongoing consolidation—is through the Health Care Select SPDR ETF (XLV), a holding in the Best Ideas portfolio. The ETF boasts Johnson & Johnson (JNJ), Pfizer (PFE), Merck (MRK), Gilead Sciences (GILD), and AbbVie (ABBV) as its top … Read more

Valuentum Economic Castleâ„¢ Rating Update

by

Read: Keeping the Horse Before the Cart: Valuentum’s Economic Castle™ Rating The Economic Castle Focuses on the Magnitude of Economic Value Creation The Valuentum Economic Castle™ rating is an enhancement of the competitive advantage framework (commonly known as economic moat analysis) that has become widespread and ubiquitous within the investing world. Whereas an economic moat framework evaluates a firm on the basis of the sustainability and durability of its competitive advantages, Valuentum’s Economic Castle™ rating evaluates a firm on the basis of the firm’s future economic profit spread (return on invested capital less its weighted average cost of capital). The companies with the strongest Valuentum Economic Castle™ ratings are poised to generate the most economic value for shareholders in the … Read more